6-Iodo-1H-Indazole CAS No.261953-36-0 Axitinib Intermediate: Axitinib is a small molecule tyrosine kinase inhibitor developed by Pfizer. It has been shown to significantly inhibit growth of breast cancer in animal (xenograft) models and has shown partial responses in clinical trials with renal cell carcinoma (RCC) and several other tumour types. Diarrhea, hypertension, fatigue, decreased appetite, nausea, dysphonia, hand-foot syndrome, weight decreased, vomiting, asthenia, and constipation are the most common side effects occurring in more than 20% of patients Product Name: 3-6-Iodo-1H-Indazole; 6-IODOINDAZOLE Cas No.: 261953-36-0 EINECS No: 607-884-2 Moculer formula: C7H5IN2 Moculer weight: 244.03 Appearance: White to brown powder Purity(By HPLC): ≥99.0% Water:≤0.5% Single Impurity: ≤0.5% Shelf time: 2 years Our productions of…
A Video Interactive Platform For Global Opportunities
Copyrights © 2024 ahollanstationery.com All Rights.Reserved .